Key facts
- Nanoligent’s last known valuation is $22.2M (Sep 2022).
- It has raised $18.0M; the latest was Later Stage VC ($14.1M) in Oct 2025.
- Notable investors include INNVIERTE SICC, Inveready Asset Management, Clave (Pamplona), Archimedes Accelerator, Avanteca Partners — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Nanoligent
- ·The full record, as it builds
Funding rounds
No funding rounds for Nanoligent are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nanoligent
Developer of nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer. The company utilizes protein engineering and nanobiotechnology to create self-assembling protein nanoparticles that selectively kill metastatic cells, enabling medical practitioners to improve patients' lives by designing medicines that target the cells affected by the disease through treatments more effective than classical drugs.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2017
- Employees
- 9
- Website
- nanoligent.com/
- Ownership
- Privately Held (backing)
Nanoligent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanoligent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanoligent in its N-PORT filings yet. We sweep new filings monthly.